Skip to main content

Hepatitis A IgM Ab

Order Code CH111
Turnaround Time 24 hours
Test Includes

Hepatitis A IgM Ab

Specimen Requirements
Specimen Source
Serum, Plasma
Transport Container
(Specimen Container)

SST (Tiger Top) Lithium Heparin/ Sodium Heparin/ Dipossium EDTA

Preferred Specimens
Minimum Volume (uL)
20 uL
Collection Instructions
(Transport Temperature)
Transport Refrigerated (cold packs)
Specimen Stability
Temperature Period
Room temperature 72 hours
Refrigerated 7 days
Frozen If delayed longer than the max RT or 2-8°C, store frozen
Test Details
chemiluminescent microparticle immunoassay (CMIA) technology
Clinical Significance

The Alinity i HAVAb IgM assay is a chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of IgM antibody to hepatitis A virus (IgM anti-HAV) in human adult and pediatric serum and plasma (dipotassium EDTA, lithium heparin, and sodium heparin) and neonatal serum on the Alinity i analyzer.

A test for IgM anti-HAV is indicated for testing of specimens from individuals who have signs and symptoms consistent with acute hepatitis. Test results are used in conjunction with other laboratory results and clinical information as an aid in the diagnosis of acute or recent hepatitis A viral infection.

Warning: Not intended for use in screening blood, plasma, or tissue donors. The effectiveness of the Alinity i HAVAb IgM assay for use in screening blood, plasma, or tissue donors has not been established. Assay performance characteristics have not been established when the Alinity i HAVAb IgM assay is used in conjunction with other manufacturers’ assays for specific hepatitis markers. Users are responsible for establishing their own performance characteristics.

The Alinity i HAVAb IgM assay determines the presence of IgM anti-HAV in human serum and plasma. Hepatitis A is typically a self-limiting disease and is often a subclinical disorder, particularly in children. Since symptomatic hepatitis A virus (HAV) infections can be clinically indistinguishable from infection with hepatitis B or C virus, serological testing is an important tool to achieve proper diagnosis. During the acute phase of HAV infection, IgM anti-HAV appears in the patient’s serum and is nearly always detectable at the onset of symptoms.In most cases, IgM anti-HAV response peaks within the first month of illness and can persist for up to six months.

Reference Ranges

No quantitative reference range

Alternative Names